Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 12/20 | 0.67 |
| ▸ | THRB | P10828 | 5/20 | 0.67 |
| ▸ | TP53 | P04637 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30402618 | 1.00 | PTGS2 (0.68) | PTGS2MAPTTHRBTP53HPGD | |
| SCHEMBL17544303 | 0.89 | MAPT (0.67) | PTGS2MAPTTHRBTP53HPGD | |
| SCHEMBL30403059 | 0.89 | MAPT (0.67) | PTGS2MAPTTHRBTP53HPGD | |
| SCHEMBL30402162 | 0.86 | MAPT (0.79) | PTGS2MAPTTHRBTP53HPGD | |
| SCHEMBL17544297 | 0.86 | MAPT (0.79) | PTGS2MAPTTHRBTP53HPGD | |
| SCHEMBL17544354 | 0.84 | MAPT (0.68) | PTGS2MAPTTHRBTP53HPGD | |
| SCHEMBL30401853 | 0.84 | MAPT (0.68) | PTGS2MAPTTHRBTP53HPGD | |
| SCHEMBL17544251 | 0.83 | MAPT (0.65) | PTGS2MAPTTHRBTP53HPGD | |
| SCHEMBL30402964 | 0.83 | MAPT (0.65) | PTGS2MAPTTHRBTP53HPGD | |
| SCHEMBL21349104 | 0.79 | KMT2A (0.67) | TP53ALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102328-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2020-04-02 | — | — | US | claimed |
| US-10479802-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2019-11-19 | — | — | US | claimed |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | claimed |
| EP-3186233-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2017-07-05 | — | — | EP | claimed |
| WO-2016033445-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | claimed |
| US-12258355-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-12083108-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | CHDI FOUNDATION, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-116655618-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| CN-107108534-B | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20200102328-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2020-04-02 | — | — | US | disclosed |
| US-10479802-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-10479802-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | disclosed |
| EP-3186233-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033445-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | PTGS2 4541/4885MAPT 8/4885THRB 2552/4885 |
| US-12083108-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | HTT, HYPK, UBQLN2 | PTGS2 4678/4885MAPT 12/4885THRB 2721/4885 |
| US-10479802-B2 | Probes for imaging huntingtin protein | HTT, HYPK, FABP7 | PTGS2 4532/4885MAPT 7/4885THRB 2432/4885 |
| US-20200102328-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | PTGS2 4541/4885MAPT 8/4885THRB 2552/4885 |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, FABP7 | PTGS2 4532/4885MAPT 7/4885THRB 2432/4885 |
| US-12258355-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | PTGS2 4541/4885MAPT 8/4885THRB 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.